At eight months of follow-up, Jynneos recipients not vaccinated against smallpox had lower binding antibody concentrations than those with infection.
The test the US Centers for Disease Control and Prevention uses to identify clade I mpox cases is 'most likely not reliable' for detection of the substrain identified in the study, the authors say.
Another mpox study today showed that dose-sparing vaccine administration of the Jynneos vaccine appeared to have worked.
Receive the latest infectious disease information.
Cases and deaths have already outpaced totals for 2024, and new outbreaks have emerged in Gambia, Cameroon, and Mozambique.
The initiative is designed to accelerate testing, sequencing, capacity building, and local manufacturing for mpox and other priority pathogens.
Health officials facing depleted vaccine supplies are also tracking upticks in Nigeria, Liberia, Kenya, and Ghana, as well as in Togo and Mozambique.
WHO experts are seeing the same chikungunya warning signs that occurred two decades ago, when the virus swept across Indian Ocean countries.
The cases were reported in northern Mozambique near the Tanzanian border.
Despite declines in 2 high-burden countries, cases are rising in Burundi, Uganda, Ghana, Kenya, Liberia, and Guinea.
Vaccine supply shortage comes at a bad time, as African countries make headway with their outbreaks and have seen good uptake in affected populations.
Amid promising signs, officials urged caution, noting that the outbreaks vary by clade, response measures, and social behaviors.
Clinical trials of Jynneos have begun or will begin soon in infants and children 2 years old and younger, and in pregnant or breastfeeding women.
Though the surge in Sierra Leone has received much of the attention, cases are also rising in two other countries in West Africa: Ghana and Liberia.
